SignatureFD
AUPH icon

SignatureFD’s Aurinia Pharmaceuticals AUPH Stock Holding History

SignatureFD’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$29.1K Buy
1,794
+1,404
+360% +$22.4K ﹤0.01% 2249
2026
Q2 		$6.62K Buy
+390
New +$6.23K ﹤0.01% 2780
2025
Q4 		– Sell
-179
Closed -$1.98K – 3418
2025
Q3 		$1.98K Hold
179
– – ﹤0.01% 2955
2025
Q2 		$1.52K Sell
179
-111
-38% -$890 ﹤0.01% 2936
2025
Q1 		$2.33K Buy
290
+43
+17% +$348 ﹤0.01% 2833
2024
Q4 		$2.22K Buy
247
+68
+38% +$555 ﹤0.01% 2841
2024
Q3 		$1.31K Hold
179
– – ﹤0.01% 2942
2024
Q2 		$1.02K Buy
+179
New +$943 ﹤0.01% 2897
2023
Q1 		– Sell
-52
Closed -$225 – 3283
2022
Q4 		$225 Buy
52
+21
+68% +$122 ﹤0.01% 3181
2022
Q3 		$0 Buy
+31
New +$268 ﹤0.01% 3107
2022
Q1 		– Sell
-140
Closed -$3K – 3136
2021
Q4 		$3K Buy
+140
New +$3.32K ﹤0.01% 2551

Other funds holding AUPH

LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Ritholtz Wealth Management
Ritholtz Wealth Management New York $6.96B AUM 24% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return

SignatureFD's AUPH Position: Q3 2026 in Review

SignatureFD increased its Aurinia Pharmaceuticals (AUPH) stake by 360% in Q3 2026, buying an estimated $22.4K and bringing the position to 1,794 shares worth $29.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2249.

SignatureFD first reported a position in AUPH in Q4 2021 and has held it in 11 quarters since. 129 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.

  • SignatureFD held 1,794 shares of Aurinia Pharmaceuticals worth $29.1K as of Q3 2026.
  • SignatureFD bought 1,404 Aurinia Pharmaceuticals shares in Q3 2026, an estimated $22.4K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #2249 holding.
  • SignatureFD first reported a position in Aurinia Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
  • 129 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.